Abstract
Atrial fibrillation is the commonest sustained arrhythmia in rheumatic heart disease and is associated with significant morbidity and mortality. In this review, we discuss its epidemiology, natural course and management with special emphasis on recent developments in understanding and treatment of atrial fibrillation in rheumatic heart disease. Use of direct oral anticoagulants appears promising, especially in developing countries where regular coagulation monitoring is a challenge. Also, restoration and maintenance of sinus rhythm in rheumatic atrial fibrillation appear feasible and may predict better clinical outcomes. Atrial fibrillation in rheumatic heart disease is not only very frequent but also a clinical marker of worse outcomes. Increasing age and left atrial size are the most important predictors for its development. The risk of thromboembolism/disabling stroke is significantly elevated when compared with that with non-valvular atrial fibrillation. Anticoagulation with vitamin K antagonists and ventricular rate control are the mainstay of therapy. However, recent evidence predicts a promising future for direct oral anticoagulants and rhythm control strategies in rheumatic atrial fibrillation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Current Treatment Options in Cardiovascular Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
